Esophagogastric cancer: targeted agents. Review uri icon

Overview

abstract

  • Because of the poor prognosis for patients with locally advanced and metastatic esophageal, gastroesophageal junction and gastric cancers, increasing attention has focused on the integration of targeted agents into current therapies. The molecular targets of these agents include epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF) or its receptor, cyclooxygenase-2 (COX-2), mammalian target of rapamycin (mTOR) and components and regulators of the cell cycle. In this review article, we briefly discuss pre-clinical data and the rationale for targeting these pathways and summarize the results of clinical trials to-date, including completed and ongoing phase III evaluations.

publication date

  • February 1, 2010

Research

keywords

  • Antineoplastic Agents
  • Esophageal Neoplasms
  • Stomach Neoplasms

Identity

Scopus Document Identifier

  • 77951203998

Digital Object Identifier (DOI)

  • 10.1016/j.ctrv.2009.12.009

PubMed ID

  • 20122806

Additional Document Info

volume

  • 36

issue

  • 3